Dr. Nancy Reid
Purpose: The purpose of this article is to review the efficacy of immunotherapy in estrogen positive metastatic breast cancer.
Method: A PubMed literature search was conducted with search terms immunotherapy, chemotherapy and metastatic breast cancer. A filter was used to access articles with free full text that were written within the last five years. The most pertinent articles were selected for this clinical review.
Results: There is not enough research available to prove that estrogen positive metastatic breast cancer tumors respond significantly to immunotherapy. Checkpoint inhibitors, microsatellite instability high, mismatch-deficiency and tumor mutation burden levels are good predictors of response. Patients with those biomarkers may seek treatment when there are no other options.
Conclusion: Additional testing is needed to justify the use of immunotherapy in estrogen positive metastatic breast cancer.
Keywords: Immunotherapy, Metastatic Breast Cancer, Tumor Mutation Burden, Mismatch Repair, Checkpoint Inhibitor.
Target Audience. The target audience is physician assistants and nurse practitioners practicing in oncology.
Price L. Is Immunotherapy An Effective Treatment Option For Estrogen Positive Metastatic Breast Cancer?. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2020; 2(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.